2023 ASKP3 Annual Conference
December 8 – 9, 2023
Austin Marriott Downtown
Austin, TX, USA
Ketamine in 2023: Celebrating Diverse Perspectives and Approaches
Join us for the 2023 ASKP3 Annual Conference, engage in dynamic conversations and networking with colleagues, and learn about the latest research and resources in ketamine and emerging treatments. This year’s Annual Conference will be hosted at the Austin Marriott Downtown in Austin, Texas, USA, and includes over 14 hours of plenary sessions and concurrent sessions as well as a robust exhibit hall offering up-to-date technology and resources for our industry.
Conference highlights include:
- Welcome Reception with Exhibitors
- Peer-reviewed abstract presentations from industry experts
- Earn up to 14 CMEs (pending approval)
Registration and Registration Rates:
| Registration Fees | Earlybird Discount (By 11/7/23) |
Regular Rates
(After 11/7/23) |
|---|---|---|
| Prescriber/Corporate/CEO MEMBER | $845 | $945 |
| Associate MEMBER | $695 | $795 |
| Resident MEMBER | $395 | $495 |
| Prescriber/Corporate/CEO NON-MEMBER | $1,195 | $1,295 |
| Associate NON-MEMBER | $795 | $895 |
| Resident NON-MEMBER | $495 | $595 |
Target Audience
This program is designed for all clinicians and multidisciplinary practitioners in the ketamine and emerging treatments industry. The American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3) is a non-profit group of professionals dedicated to the safe clinical use of ketamine for mental health disorders and pain conditions.
Attendee Cancellation Policy
Full payment is due at the time of registration. A refund less a $100 processing fee will be given for cancellations that submit a written request to ASKP3. Requests must be received by November 7, 2023. No refunds will be given after November 7, 2023. Requests must be submitted to info@askp.org. In the event that the program is canceled or postponed, we will not be responsible for any travel costs or expenses, including cancellation/change penalties assessed by airlines, travel agencies or hotels.
Preliminary Attendee Schedule* (*subject to change; CME/CEs pending approval)
11:30 a.m. – 6:30 p.m: Registration: Pick Up Your Badge and Materials | Waller Ballroom Foyer – Level 3
12:00 p.m. – 1:00 p.m: ASKP3 Expert Faculty Lunch (invitation only)
1:00 p.m. – 5:30 p.m: ASKP3 Expert Faculty: Mapping the Future (invitation only)
5:30 p.m. – 7:30 p.m: Exhibit Hall Open | Moontower – Level 2
6:00 p.m. – 7:30 p.m: Attendee, Expert Faculty, and Exhibitor Welcome Reception | Moontower – Level 2
7:00 a.m. – 5:00 p.m: Registration Open | Waller Ballroom Foyer – Level 3
7:00 a.m. – 5:30 p.m: Exhibit Hall Open | Moontower – Level 2
7:00 a.m. – 8:00 a.m: Attendee and Exhibitor Breakfast | Moontower – Level 2
8:00 a.m. – 8:10 a.m: Welcome and Opening Remarks | Sandhya Prashad, MD | Waller Ballroom – Level 3
8:10 a.m. – 8:30 a.m: ASKP3 Standards of Practice | Sandhya Prashad, MD and Patrick Sullivan, MD | Waller Ballroom – Level 3
8:30 a.m. – 9:15 a.m: Ketamine: Catalyst for Paradigm Change in Mental Health I Scott Shannon, MD | Waller Ballroom – Level 3
9:15 a.m. – 10:15 a.m: Dosing Panel and Q&A | ASKP3 Board of Directors | Waller Ballroom – Level 3
10:15 a.m. – 10:45 a.m: Networking Break with Exhibitors | Moontower – Level 2
10:45 a.m. – 11:30 a.m: Analysis of 1,000 Patients and 10,000 IV Ketamine Infusions for Patients with Mood Disorders, Suicidal Ideations and Thoughts, and Predictive Analytics | Patrick Oliver, MD | Waller Ballroom – Level 3
11:30 a.m. – 12:30 p.m: Five-Year Retrospective Analysis of Ketamine Treatments: IV, IM, KAP and Ketamine Only | Brent Turnipseed, MD | Waller Ballroom – Level 3
12:30 p.m. – 1:30 p.m: Lunch with Exhibitors | Moontower – Level 2
1:30 p.m. – 2:15 p.m: Sub-Dissociative Dose Ketamine for Chronic Pain, Depression and Beyond | Lucinda Grande, MD and Angelo De Gioannis, MD | Waller Ballroom – Level 3
2:15 p.m. – 3:15 p.m: Fundamentals of an Oral Ketamine Service | Lucinda Grande, MD and Angelo De Gioannis, MD | Waller Ballroom – Level 3
3:15 p.m. – 3:45 p.m: Networking Break with Exhibitors | Moontower – Level 2
3:45 p.m. – 4:45 p.m: Concurrent Breakout Sessions (attendees select one)
Sub-Dissociative Ketamine: An Interactive Session | Lucinda Grande, MD and Angelo De Gioannis, MD
When Ketamine Doesn’t Work | Sandhya Prashad, MD and Erin Amato, MD
KAP | Jeffrey Becker, MD and Gita Vaid, MD
What is “Safe” and Who Gets to Decide? A Collaborative Assessment for Psychedelic-Assisted Therapy | Irina Alexander, LMFT and Vilmarie Fraguada Narloch, PsyD
5:00 p.m. – 6:00 p.m: Concurrent Breakout Sessions (attendees select one)
MSKIT: The Application of Ketamine in Chronic Pain Treatment | Charles Miller, CRNA
Healing in Community: A Group KAP Approach | Katja Cahoon, LCSW
TMS + Ketamine | Sandhya Prashad, MD and Patrick Sullivan, DO
Eight Pillars of Training in Ketamine-Assisted Psychotherapy | Harvey Schwartz, Phd; Eric Sienknecht, PsyD; and Veronika Gold, LMFT
7:00 a.m. – 5:00 p.m: Registration Open | Waller Ballroom Foyer – Level 3
7:00 a.m. – 5:00 p.m: Exhibit Hall Open | Moontower – Level 2
7:00 a.m. – 8:00 a.m: Attendee and Exhibitor Breakfast | Moontower – Level 2
8:00 a.m. – 8:45 a.m: Machine Learning Algorithms for Prediction of Treatment Response to Ketamine Infusion Therapy | Albert Arias, MD; Patrick Oliver, MD; and Matthew Worley, PhD | Waller Ballroom – Level 3
8:45 a.m. – 9:45 a.m: Psychodrama and KAP: A Complementary, Synergistic Healing Approach | Gita Vaid, MD; Linda Thai, LMSW; and Monica Winsor, LMFT | Waller Ballroom – Level 3
9:45 a.m. – 10:00 a.m: Break with Exhibitors | Moontower – Level 2
10:00 a.m. – 10:50 a.m: Concurrent Breakout Sessions (attendees select one)
Everyone Wins: How to Make Ketamine Both Affordable and Sustainable | Andrea Turnipseed, LCSW-S
Dissociation as a Therapeutic Mechanism of Ketamine Treatment | Farid Alsabeth, MLP
Spravato: Where Does it Fit in the Treatment Algorithm? | Erin Amato, MD and Sandhya Prashad, MD
Eight Pillars of Training in Ketamine-Assisted Psychotherapy | Harvey Schwartz, PhD, Eric Sienknecht, PsyD; and Veronika Gold, LMFT
11:00 a.m. – 11:50 a.m: Concurrent Sessions (attendees select one)
Psychedelic Emergencies and Integrative First Aid | Jordan Dobrowski, LCSW, CPTAP and Judy Seals, FNP-C
Everyone Wins: How to Make Ketamine Both Affordable and Sustainable | Andrea Turnipseed, LCSW-S
Efficacy of IV Esketamine in Real-World Setting for Depressive Symptoms of Bipolar/Unipolar Disorder | Tiago Gil, MD
Psychedelic Treatments, Documentation, and Enforcement | Harriet Wall
12:00 p.m. – 12:45 p.m: Ketamine vs. ECT: Perspectives on Comparative Effectiveness | Sanjay Mathew, MD | Waller Ballroom – Level 3
12:45 p.m. – 1:45 p.m.: Attendee and Exhibitor Lunch | Moontower – Level 2
1:45 p.m. – 2:15 p.m: Introduction of Expert Faculty | Waller Ballroom – Level 3
2:15 p.m. – 3:15 p.m: New Chemical Entity Horizons in Serotonergic Psychedelic and Dissociative Agents | Jason Wallach, PhD |Waller Ballroom – Level 3
3:15 p.m. – 4:00 p.m: Advocacy 101 | Evan Autrey | Waller Ballroom – Level 3
4:00 p.m. – 4:30 p.m: Break with Exhibitors | Moontower – Level 2
4:30 p.m. – 5:30 p.m: Legal Considerations in Ketamine | Sean McAllister, Esq. and Daniel Sternthal | Waller Ballroom – Level 3
5:30 p.m. – 6:00 p.m: Practice Patterns and Medical Provider Perceptions of Ketamine in the Treatment of Psychiatric Disorders: A Nationwide Study | Amna Aslam, MBA | Waller Ballroom – Level 3
6:00 p.m. – 6:15 p.m: Closing Remarks | Sandhya Prashad, MD | Waller Ballroom – Level 3
Poster Presentations
A number of peer-reviewed Poster Presentations will be available at the Annual Conference, including:
PRO Monitoring in a Mental Health Practice to Track Response to Ketamine and Other Treatments | Victoria Hahn, MS, RDN
Ketamine Assisted Psychotherapy with Low-Income Culturally Diverse Patients | Dave Rojas, MA
Ketamine: The Solution for Improving Mental Health | Jasmine Bonder, DNP, MSN, ACNP-BC-RN and Carl Bonnett, MD
Efficacy and Dissociative Side Effects of Ketamine Infusion Therapy | Satyen Madkaiker
Sustained Therapeutic Outcomes in Clinical Psychiatry: A Case Series Comparing the Efficacy of Intranasal and Intravenous Ketamine | Amna Aslam, MBA; Joshua Fleishman, PharmD Candidate; Rajesk Nayak, PhD; and Sandhya Prashad, MD
Hotel Accommodations
ASKP3 has secured discounted room rates at the Austin Marriott Downtown in Austin, Texas, USA. The discounted room rate is $229/night plus applicable taxes. Ask for the “ASKP” rate when booking your room.
Book your sleeping room accommodations by November 15 to take advantage of the discounted room rate. Discounted rate available until rooms sell out.
Austin Marriott Downtown
304 East Cesar Chavez Street
Austin, TX 78701
Click here for online booking.
Please note: ASKP3 does not partner with any third-party hotel vendors. Please book directly with the Austin Marriott Downtown.
Faculty
ASKP3 issued a Call for Abstracts for presentation at the 2023 Annual Conference. Abstracts were peer-reviewed and identified for presentation. Additional expert speakers were also invited to present. Our full list of Annual Conference Speakers is below.
2023 ASKP3 Annual Conference Speakers
Farid Alsabeh, TLLP
- Dissociation as a Therapeutic Mechanism of Ketamine Treatment
Irina Alexander, LMFT
- What is "Safe" and Who Gets to Decide? A Collaborative Assessment for Psychedelicassisted Therapy
Erin Amato, MD
- When Ketamine Doesn't Work
- Spravato
Albert Arias, MD, MS
- Machine Learning Algorithms for Prediction of Treatment Response to Ketamine Infusion Therapy
Amna Aslam, MBA
- Practice Patterns and Medical Provider Perceptions of Ketamine in the Treatment of Psychiatric Disorders: A Nationwide Study
Evan Autry
- Session “Advocacy 101: Legislative Processes and Advocacy in Healthcare”
Jeffrey Becker, MD
- KAP: Pulse Dosing
Jasmine Bonder, DNP, MSN, ACNP-BC, RN
- Economic Efficacy of Mental Health Services
Katja Cahoon, LCSW, MBA
- Healing in Community: A KAP Group Approach
Angelo DeGioannis, MD
- Fundamentals of an Oral Ketamine Service
Jordan Dobrowski, LCSW, CPATP
- Psychedelic Ketamine Emergencies and Integrative First Aid
Tiago Gil, MD
- Effect of Intravenous Esketamine in Reducing Depressive Symptoms and Suicidal Ideation in Real-World, Single Center, Retrospective Chart Review
Veronika Gold, LMFT
- Eight Pillars of Training in Ketamine-Assisted Psychotherapy (KAP)
Lucinda Grande, MD
- Sub-Dissociative Dose Ketamine for Chronic Pain, Depression, and Beyond
Victoria Hahn, MS, RDN
- PRO Monitoring in a Mental Health Practice to Track Response to Ketamine and Other Treatments
Satyen Madkaiker
- Efficacy and Dissociative Side Effects of Ketamine Infusion Therapy
Sanjay Mathew, MD
- ECT v. Ketamine
Sean McAllister, Esq.
- Legal Review of Ketamine Therapy and Prescriptions
Charles Miller, CRNA
- The Use of Ketamine Infusions in Pain Management
Vilmarie Fraguada Narloch, PsyD
- What is "Safe" and Who Gets to Decide? A Collaborative Assessment for Psychedelic Assisted Therapy
Rajesh Nayak, B.S. Pharm., M.S. Pharm., Ph.D.
- IV Ketamine v. Intranasal Esketamine in Clinical Practice
Patrick Oliver, MD
- Subanalysis of 10,000 Infusions of Racemic Ketamine in a Large Community Sample of Patients With TRD
Sandhya Prashad, MD
- When Ketamine Doesn’t Work
- Spravato
- ASKP3 Standards of Practice
- TMS + Ketamine
Dave Rojas, M.A.
- Ketamine Assisted Psychotherapy with Low-Income Culturally Diverse Patients
Harvey Schwartz, Ph.D.
- Eight Pillars of Training in Ketamine-Assisted Psychotherapy (KAP)
Judy Seals, FNP-C
- Psychedelic Ketamine Emergencies and Integrative First Aid
Scott Shannon, MD
- Ketamine: Catalyst for Paradigm Change in Mental Health
Eric Sienknecht, PsyD
- Eight Pillars of Training in Ketamine-Assisted Psychotherapy (KAP)
Daniel Sternthal, JD
- Legal Considerations in the Ketamine Space
Patrick Sullivan, DO
- ASKP3 Standards of Practice
Linda Thai, LMSW ERYT-200
- Psychodrama and KAP: A Complementary, Synergistic Healing Approach
Andrea Turnipseed, LCSW-S
- Everyone Wins: How to Make Ketamine Both Affordable and Profitable
Brent Turnipseed, MD
- Machine Learning (ML) Algorithms for Prediction of Treatment Response to Ketamine Infusion Therapy (KIT)
Gita Vaid, MD
- KAP
- Psychodrama and KAP: A Complementary, Synergistic Healing Approach
Harriett Wall
- Psychedelic Treatments, Documentation, and Enforcement
Jason Wallach, Ph.D.
- New Chemical Entity Horizons in Serotonergic Psychedelic and Dissociative Agents
Monica Winsor, LMFT
- Psychodrama and KAP: A Complementary, Synergistic Healing Approach
Thomas Woods, B.A.
- Efficacy and Dissociative Side Effects of Ketamine Infusion Therapy
Matthew Worley, PhD, MPH
- Machine Learning Algorithms for Prediction of Treatment Response to Ketamine Infusion Therapy
How to Receive CME Credit
To receive CME credits, ASKP3 has partnered with PeerPoint. Attendees will be provided instructions on self-reporting to PeerPoint following completion of the program.
Disclaimer
The information provided at this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Statements by industry representatives during the program may not reflect the views and opinions of the ASKP3, its Board of Directors, faculty, or staff